vs
Side-by-side financial comparison of LISATA THERAPEUTICS, INC. (LSTA) and MEDICINOVA INC (MNOV). Click either name above to swap in a different company.
MEDICINOVA INC is the larger business by last-quarter revenue ($123.3K vs $100.0K, roughly 1.2× LISATA THERAPEUTICS, INC.). MEDICINOVA INC produced more free cash flow last quarter ($-1.7M vs $-16.0M).
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Medicinova Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for unmet medical needs, focusing on immunology, inflammatory disorders and oncology. It operates across North America and Asia, advancing pipeline candidates through clinical trials to serve patients with limited treatment options.
LSTA vs MNOV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $100.0K | $123.3K |
| Net Profit | — | $-3.1M |
| Gross Margin | — | — |
| Operating Margin | — | -2741.7% |
| Net Margin | — | -2473.6% |
| Revenue YoY | -90.0% | — |
| Net Profit YoY | 35.9% | -6.9% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $100.0K | — | ||
| Q3 25 | $0 | $123.3K | ||
| Q2 25 | $70.0K | $134.6K | ||
| Q1 25 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q4 25 | — | — | ||
| Q3 25 | $-4.2M | $-3.1M | ||
| Q2 25 | $-4.7M | $-3.3M | ||
| Q1 25 | $-4.7M | — | ||
| Q3 24 | $-4.9M | — | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-5.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -2741.7% | ||
| Q2 25 | -6954.3% | -2679.9% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -2473.6% | ||
| Q2 25 | -6655.7% | -2437.7% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.49 | $-0.06 | ||
| Q2 25 | $-0.54 | $-0.07 | ||
| Q1 25 | $-0.55 | — | ||
| Q3 24 | $-0.59 | — | ||
| Q2 24 | $-0.61 | — | ||
| Q1 24 | $-0.65 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.0M | $32.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.9M | $44.0M |
| Total Assets | $17.7M | $47.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.0M | — | ||
| Q3 25 | $19.0M | $32.6M | ||
| Q2 25 | $16.8M | $34.3M | ||
| Q1 25 | $20.2M | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $28.3M | — | ||
| Q1 24 | $21.8M | — |
| Q4 25 | $14.9M | — | ||
| Q3 25 | $17.4M | $44.0M | ||
| Q2 25 | $21.0M | $46.9M | ||
| Q1 25 | $25.4M | — | ||
| Q3 24 | $33.7M | — | ||
| Q2 24 | $38.2M | — | ||
| Q1 24 | $43.0M | — |
| Q4 25 | $17.7M | — | ||
| Q3 25 | $21.8M | $47.6M | ||
| Q2 25 | $25.2M | $49.8M | ||
| Q1 25 | $29.0M | — | ||
| Q3 24 | $38.2M | — | ||
| Q2 24 | $42.6M | — | ||
| Q1 24 | $48.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.9M | $-1.7M |
| Free Cash FlowOCF − Capex | $-16.0M | $-1.7M |
| FCF MarginFCF / Revenue | -15977.0% | -1383.5% |
| Capex IntensityCapex / Revenue | 28.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $-3.3M | $-1.7M | ||
| Q2 25 | $-4.0M | $-2.3M | ||
| Q1 25 | $-5.4M | — | ||
| Q3 24 | $-2.5M | — | ||
| Q2 24 | $-5.3M | — | ||
| Q1 24 | $-7.0M | — |
| Q4 25 | $-16.0M | — | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | $-5.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -15977.0% | — | ||
| Q3 25 | — | -1383.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 28.0% | — | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
